Approximately 23% of patients with CVF that are treated with TVE will require retreatment. Symptom recurrence is most common within 3 months after initial treatment. Recurrence can occur due to local treatment failure or development of collateral drainage pathways, but a substantial proportion of patients develop de novo CVFs remote from the initial treatment site. These findings can be used to counsel patients and to manage treatment expectations.
Schartz et al. (2026) studied this question.